Ellin Berman is a board-certified medical oncologist and hematologist with a clinical and research focus on new drug development in acute and chronic leukemias, including acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). As a member of the multidisciplinary Leukemia Disease Management Team at Memorial Sloan Kettering Cancer Center (MSKCC), she works closely with the many individuals who make up the clinical and research programs there. Along with other members of the Leukemia Service, she is involved in clinical trials of new drugs that hopefully will lead to new treatment approaches for these diseases. She has also worked closely with the Food and Drug Administration in this regard, and for the last 20 years have helped review new drug applications for the treatment of leukemia. She is a member of KSKCC’s Institutional Review Board (IRB), the committee that approves, monitors, and reviews research studies at the Center. She is an Associate Editor for the journal Leukemia Research, and reviews articles for a number of other journals including Blood, the Journal of Clinical Oncology, Cancer Research, The Lancet, and the New England Journal of Medicine.